Aquestive Therapeutics, Inc. (NASDAQ:AQST) Holdings Decreased by Legato Capital Management LLC

Legato Capital Management LLC decreased its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 23.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 186,424 shares of the company’s stock after selling 55,947 shares during the period. Legato Capital Management LLC owned 0.20% of Aquestive Therapeutics worth $664,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Harvey Capital Management Inc. boosted its position in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after purchasing an additional 249,790 shares during the last quarter. Financial Advocates Investment Management boosted its position in Aquestive Therapeutics by 28.2% during the fourth quarter. Financial Advocates Investment Management now owns 50,000 shares of the company’s stock valued at $178,000 after purchasing an additional 11,000 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Aquestive Therapeutics during the fourth quarter valued at $69,000. Janney Montgomery Scott LLC boosted its position in Aquestive Therapeutics by 6.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock valued at $3,505,000 after purchasing an additional 61,200 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Aquestive Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after purchasing an additional 7,347 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Leerink Partners lifted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Finally, Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $3.47 on Friday. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $6.23. The business has a 50-day moving average of $3.36 and a two-hundred day moving average of $4.20. The stock has a market capitalization of $316.39 million, a P/E ratio of -7.71 and a beta of 2.67.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.